Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
J Hepatol ; 62(6): 1237-45, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25559326

ABSTRACT

BACKGROUND & AIMS: New therapies for chronic hepatitis B (CHB) are urgently needed since current treatments rarely lead to cure. We evaluated whether the oral small molecule toll-like receptor (TLR7) agonist GS-9620 could induce durable antiviral efficacy in woodchucks chronically infected with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to human hepatitis B virus (HBV). METHODS: After evaluating the pharmacokinetics, pharmacodynamics and tolerability of oral GS-9620 in uninfected woodchucks, adult woodchucks chronically infected with WHV (n = 7 per group) were dosed with GS-9620 or placebo for 4 or 8 weeks with different treatment schedules. RESULTS: GS-9620 treatment induced rapid, marked and sustained reduction in serum viral DNA (mean maximal 6.2log10 reduction), and hepatic WHV DNA replicative intermediates, WHV cccDNA and WHV RNA, as well as loss of detectable serum WHV surface antigen (WHsAg). GS-9620 treatment also induced a sustained antibody response against WHsAg in a subset of animals. Strikingly, treatment reduced the incidence of hepatocellular carcinoma (HCC) from 71% in the placebo group to 8% in GS-9620-treated woodchucks with sustained viral load reduction. GS-9620 treatment was associated with reversible increases in serum liver enzymes and thrombocytopenia, and induced intrahepatic CD8(+) T cell, NK cell, B cell and interferon response transcriptional signatures. CONCLUSIONS: The data demonstrate that short duration, finite treatment with the oral TLR7 agonist GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB, and support investigation of this compound as a therapeutic approach to attain a functional cure in CHB patients.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis B Virus, Woodchuck , Hepatitis B/drug therapy , Hepatitis B/immunology , Pteridines/therapeutic use , Toll-Like Receptor 7/agonists , Animals , Antiviral Agents/pharmacokinetics , DNA, Viral/blood , Disease Models, Animal , Hepatitis Antibodies/blood , Hepatitis Antigens/blood , Hepatitis B/complications , Hepatitis B Virus, Woodchuck/drug effects , Hepatitis B Virus, Woodchuck/genetics , Hepatitis B Virus, Woodchuck/isolation & purification , Humans , Liver Neoplasms, Experimental/etiology , Liver Neoplasms, Experimental/prevention & control , Male , Marmota , Pteridines/pharmacokinetics , Seroconversion/drug effects , Time Factors , Treatment Outcome
3.
J Virol ; 85(10): 4853-62, 2011 May.
Article in English | MEDLINE | ID: mdl-21389124

ABSTRACT

The development of therapeutic vaccines for chronic hepatitis B virus (HBV) infection has been hampered by host immune tolerance and the generally low magnitude and inconsistent immune responses to conventional vaccines and proposed new delivery methods. Electroporation (EP) for plasmid DNA (pDNA) vaccine delivery has demonstrated the enhanced immunogenicity of HBV antigens in various animal models. In the present study, the efficiency of the EP-based delivery of pDNA expressing various reporter genes first was evaluated in normal woodchucks, and then the immunogenicity of an analog woodchuck hepatitis virus (WHV) surface antigen (WHsAg) pDNA vaccine was studied in this model. The expression of reporter genes was greatly increased when the cellular uptake of pDNA was facilitated by EP. The EP of WHsAg-pDNA resulted in enhanced, dose-dependent antibody and T-cell responses to WHsAg compared to those of the conventional hypodermic needle injection of WHsAg-pDNA. Although subunit WHsAg protein vaccine elicited higher antibody titers than the DNA vaccine delivered with EP, T-cell response rates were comparable. However, in WHsAg-stimulated mononuclear cell cultures, the mRNA expression of CD4 and CD8 leukocyte surface markers and Th1 cytokines was more frequent and was skewed following DNA vaccination compared to that of protein immunization. Thus, the EP-based vaccination of normal woodchucks with pDNA-WHsAg induced a skew in the Th1/Th2 balance toward Th1 immune responses, which may be considered more appropriate for approaches involving therapeutic vaccines to treat chronic HBV infection.


Subject(s)
Antigens, Surface/immunology , Electroporation , Hepatitis B Vaccines/immunology , Hepatitis B Virus, Woodchuck/immunology , Vaccination/methods , Vaccines, DNA/immunology , Viral Proteins/immunology , Animals , Antibodies, Viral/blood , Antigens, Surface/genetics , Female , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/genetics , Hepatitis B Virus, Woodchuck/genetics , Marmota , Plasmids , T-Lymphocytes/immunology , Th1 Cells/immunology , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Viral Proteins/genetics
4.
J Virol ; 83(23): 12266-78, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19740992

ABSTRACT

A vector based on Semliki Forest virus (SFV) expressing high levels of interleukin-12 (SFV-enhIL-12) has previously demonstrated potent antitumoral efficacy in small rodents with hepatocellular carcinoma (HCC) induced by transplantation of tumor cells. In the present study, the infectivity and antitumoral/antiviral effects of SFV vectors were evaluated in the clinically more relevant woodchuck model, in which primary HCC is induced by chronic infection with woodchuck hepatitis virus (WHV). Intratumoral injection of SFV vectors expressing luciferase or IL-12 resulted in high reporter gene activity within tumors and cytokine secretion into serum, respectively, demonstrating that SFV vectors infect woodchuck tumor cells. For evaluating antitumoral efficacy, woodchuck tumors were injected with increasing doses of SFV-enhIL-12, and tumor size was measured by ultrasonography following treatment. In five (83%) of six woodchucks, a dose-dependent, partial tumor remission was observed, with reductions in tumor volume of up to 80%, but tumor growth was restored thereafter. Intratumoral treatment further produced transient changes in WHV viremia and antigenemia, with >or=1.5-log(10) reductions in serum WHV DNA in half of the woodchucks. Antitumoral and antiviral effects were associated with T-cell responses to tumor and WHV antigens and with expression of CD4 and CD8 markers, gamma interferon, and tumor necrosis factor alpha in peripheral blood mononuclear cells, suggesting that immune responses against WHV and HCC had been induced. These experimental observations suggest that intratumoral administration of SFV-enhIL-12 may represent a strategy for treatment of chronic HBV infection and associated HCC in humans but indicate that this approach could benefit from further improvements.


Subject(s)
Carcinoma, Hepatocellular/veterinary , Hepatitis B Vaccines/immunology , Hepatitis B, Chronic/veterinary , Interleukin-12/immunology , Semliki forest virus/immunology , Animals , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/therapy , Female , Hepatitis B Virus, Woodchuck/immunology , Hepatitis B Virus, Woodchuck/isolation & purification , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/therapy , Immunotherapy/methods , Interferon-gamma/biosynthesis , Interleukin-12/genetics , Liver/diagnostic imaging , Liver/pathology , Male , Marmota , Semliki forest virus/genetics , Tumor Necrosis Factor-alpha/biosynthesis , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...